| Cat.No. | Name | Information |
|---|---|---|
| M3835 | Alirocumab | Alirocumab is a humanized IgG1 PCSK9 monoclonal antibody that can be used in the study of hypercholesterolemia. |
| M56732 | PCSK9-IN-13 | PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM. |
| M55020 | AZD0780 | AZD0780 (PCSK9-IN-12, EX-A6975) is an oral, potentially first-in-class small molecule inhibitor of PCSK9. AZD0780 (PCSK9-IN-12, EX-A6975) has bind affinity for PCSK9 with a Kd value of ＜200 nM. AZD0780 (PCSK9-IN-12, EX-A6975) can be used for the research of cholesterol metabolism. |
| M28735 | PF-06446846 | PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region. |
| M24947 | Ongericimab | Ongericimab (JS002) is a humanized anti-PCSK9 IgG4ҡ monoclonal antibody for hypercholesterolemia and hyperlipidemia. |
| M24769 | Frovocimab | Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9. |
| M11343 | Pinostrobin | Pinostrobin is a flavonoid found in many plants and has antioxidant, anti-inflammatory, anticancer and neuroprotective properties. Pinostrobin is an effective INHIBITOR of PCSK9, which can inhibit the catalytic activity of PCSK9. Pinostrobin is a promising agent for cholesterol regulation and lipid management. |
| M11162 | Pep2-8 | Pep2-8 is a PCSK9 inhibitor, of which KD The value is 0.7 μM,IC50 The value is 1.4 μM. |
| M10699 | SBC-115337 | SBC-115337 is a potent benzofuran compound that is an inhibitor of PCSK9,IC50 The value is 0.5 μM. |
| M9966 | PF-06446846 hydrochloride | PF-06446846 hydrochloride is a selective orally active PCSK9 inhibitor that appears to act by causing the ribosome to stall when synthesizing PCSK9. |
| M9867 | SBC-110736 | SBC-110736 is a novel inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9). |
| M7542 | SBC-115076 | Sbc-115076 is an effective inhibitor of the preprotein invertase Bacillus subtilis proteinase/Kexin 9 (PCSK9). PCSK9 is a preprotein invertase that plays an important role in LDL receptor metabolism. |
| M6251 | R-IMPP | R-impp (PF-00932239) is an anti-secreting inhibitor of PCSK9 (IC50=4.8 μM), which can inhibit PCSK9 protein translation by targeting the ribosomes at the time of 80S. |
| M4247 | Schizandrol-B | Schisantherin B (Gomisin-B; Wuweizi ester-B; Schisantherin-B) is a lignan from Schisandra chinensis that promotes liver enlargement in mice through activation of the PXR and YAP pathways and inhibits PCSK9 protein expression with an IC50 value of 1.10 μM. |
| M1595 | Evolocumab | Evolocumab (AMG 145) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. |
| M56731 | PCSK9 ligand 1 | PCSK9 ligand 1 is a selective proprotein convertase substilisin-like/kexin type 9 (PCSK9) ligand. |
| M45130 | NNC0385-0434 | NNC0385-0434 is a peptide based on the epidermal growth-factor-like domain A of the human LDLR peptide. NNC0385-0434 competitively binds free PCSK9 and subsequently prevents PCSK9 binding to the LDLR. NNC0385-0434 is an orally active peptide small molecule PCSK9 inhibitor for atherosclerosis-related studies. |
| M45129 | CiVi-008 | CiVi-008 is an orally active PCSK9 antisense oligonucleotide (ASO) inhibitor for studies related to disorders of lipid metabolism. |
| M45128 | CiVi-007 | CiVi-007 is an antisense oligonucleotide (ASO) polymerized with N-acetylglucosamine that targets PCSK9 and can be used in studies related to hypercholesterolemia. |
| M45125 | AZD-8233 | AZD-8233 is an orally active, antisense oligonucleotide (ASO) targeting PCSK9 that targets and inhibits the translation and protein synthesis of PCSK9 mRNA in hepatocytes and reduces circulating LDL-C levels. It can be used in studies related to hypercholesterolemia. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
